Jason Lettmann

Jason Lettmann General Information

Biography

Mr. Jason Lettmann serves as Chief Executive Officer at ALX Oncology. He served as a General Partner at Lightstone Ventures. He serves as an Investment Advisory Board Member at Michigan Biomedical Venture Fund. He serves as a Board Member at Cerevance. He served as a Board Member at Atsena Therapeutics. He served as a Board Member at Fire1. He served as Chief Executive Officer and Board Member at Promedior. He also served as a Board Member at Vapotherm. He also serves as a Partner at Morgenthaler Ventures. He is also a Board Member of Ra Pharmaceuticals. He focuses on medical device and biopharmaceutical investments and brings 15 years of operating and venture experience in the life science sector. He served as a Board Member at Carrick Therapeutics. He currently represents Lightstone on the board of FIRE1 and represents Morgenthaler on the boards of Relievant Medsystems and Second Genome. Before Lightstone, he was a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013. He was also a board observer at Ardian (acquired by Medtronic in 2011) and Cabochon Aesthetics (acquired by Ulthera in 2014). Before joining Morgenthaler, he was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. During his time at Split Rock, he was actively involved with the firm's investments in Atritech (acquired by Boston Scientific), Entellus Medical, EBR Systems, Evalve (acquired by Abbott Labs), Miramar Labs as well as with the founding of Zyga Technologies. Before Split Rock, His experience includes tenure with Guidant Corporation's Compass Group, which focused on corporate venture and business development, as well as a Consultant with Accenture's Health and Life Science practice, where he advised clients across the medical device and pharmaceutical and healthcare payer sectors. He also previously worked as a Genetic Research Analyst at the University of Iowa Hospitals and Clinics. He served as a Board Member at Second Genome. He holds an M.B.A. with distinction from the University of Michigan's Ross School of Business and a B.A. with honors from the University of Iowa.